Catalyst Wire Dossier Catalyst Wire Dossier

Anti-vascular Endothelial Growth Factor plus Anti-angiopoietin 2 in Fixed combination therapy

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Anti-vascular Endothelial Growth Factor plus Anti-angiopoietin 2 in Fixed combination therapy, covering 2018-10-03 to 2018-10-03. Get the full timeline:

Most recent: Clinical Trial Update: Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema [Phase 2]

See pricing